Resistance to anti-PD-1 therapy is driven by CD30+ regulatory T cell activity Summary Resistance to anti-PD-1 immunotherapy, a common cancer treatment, is often linked to the suppressive activity of CD30-expressing regulatory T cells (Tregs). Read More